TABLE 1.

Expression of IRF-4 in CNS lymphoma specimens^a

Case	Age of patient (yr)	CNS disease	Gender	Expression level
				EBV LMP-1	IRF-4
1	47	AIDS	Female	+++	+
2	38	AIDS	Male	++	+
3	58	AIDS	Female	+	+
4	62	AIDS	Female	+	−
5	35	AIDS	Male	++	+
6	62	AIDS	Female	++	−
7	38	AIDS	Male	+	−
8	69	AIDS	Female	+++	−
9	27	AIDS	Male	++	++
10	42	AIDS	Male	+++	++
11	39	AIDS	Male	+	+
12	49	AIDS, CMV	Male	+	−
13	77	AIDS, toxoplasmosis	Female	+	−
14	80	Alzheimer's disease	Male	−	−
15	63	Schizophrenia	Female	−	−
16	60	NR	Male	+++	+
17	82	NR	Male	−	−
18	69	NR	Male	+++	+
19	67	NR	Male	++	−
20	79	NR	Male	+	++
21	76	NR	Male	++	++
22	72	NR	Female	+	−
23	78	NR	Female	+	−
24	65	NR	Female	+	−
25	86	NR	Male	+	−
26	67	NR	Female	+	−
27	69	NR	Female	++	+

^aThe diagnosis of primary CNS lymphoma was based on the World Health Organization classification of brain tumors. CMV, cytomegalovirus; NR, no report on the clinical history. LMP-1 is used to represent the status of EBV; the data for LMP-1 were described previously (78) and are presented here for the benefit of the readers. “−,” negative reactivity; “+,” 1 to 30% cell positivity; “++,” 31 to 60% cell positivity; “+++,” >60% cell positivity. The association between expression levels of LMP-1 and IRF-4 is statistically significant (R = 0.479; F = 7.444; P = 0.011). Multiple regression analysis was done with Microsoft Excel.